These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
666 related articles for article (PubMed ID: 33403970)
81. Feasibility and Educational Value of a Student-Run Pharmacovigilance Programme: A Prospective Cohort Study. Schutte T; Tichelaar J; Reumerman MO; van Eekeren R; Rolfes L; van Puijenbroek EP; Richir MC; van Agtmael MA Drug Saf; 2017 May; 40(5):409-418. PubMed ID: 28120270 [TBL] [Abstract][Full Text] [Related]
82. Patients' contribution to drug safety in Catalonia: the interest of personal feelings on adverse drug reactions. Riera-Arnau J; Alvarado Aguirre LA; Garcia Doladé N; Vidal Guitart X; Figueras A; Cereza García G Eur J Clin Pharmacol; 2021 Apr; 77(4):637-642. PubMed ID: 33170306 [TBL] [Abstract][Full Text] [Related]
83. Characterization of serious adverse drug reactions as cause of emergency department visit in children: a 5-years active pharmacovigilance study. Lombardi N; Crescioli G; Bettiol A; Marconi E; Vitiello A; Bonaiuti R; Calvani AM; Masi S; Lucenteforte E; Mugelli A; Giovannelli L; Vannacci A BMC Pharmacol Toxicol; 2018 Apr; 19(1):16. PubMed ID: 29661234 [TBL] [Abstract][Full Text] [Related]
84. Enhanced Paediatric Pharmacovigilance at the European Medicines Agency: A Novel Query Applied to Adverse Drug Reaction Reports. Blake KV; Saint-Raymond A; Zaccaria C; Domergue F; Pelle B; Slattery J Paediatr Drugs; 2016 Feb; 18(1):55-63. PubMed ID: 26597489 [TBL] [Abstract][Full Text] [Related]
85. Serious adverse drug reactions at two children's hospitals in South Africa. Mouton JP; Fortuin-de Smidt MC; Jobanputra N; Mehta U; Stewart A; de Waal R; Technau KG; Argent A; Kroon M; Scott C; Cohen K BMC Pediatr; 2020 Jan; 20(1):3. PubMed ID: 31901244 [TBL] [Abstract][Full Text] [Related]
86. Adverse drug reaction monitoring in a secondary care hospital in South India. Arulmani R; Rajendran SD; Suresh B Br J Clin Pharmacol; 2008 Feb; 65(2):210-6. PubMed ID: 17662089 [TBL] [Abstract][Full Text] [Related]
87. Adverse drug reactions: trends in a tertiary care hospital. Rehan HS; Chopra D; Sah RK; Mishra R Curr Drug Saf; 2012 Nov; 7(5):384-8. PubMed ID: 23150923 [TBL] [Abstract][Full Text] [Related]
89. Pharmacovigilance in India: Present Scenario and Future Challenges. Kalaiselvan V; Srivastava S; Singh A; Gupta SK Drug Saf; 2019 Mar; 42(3):339-346. PubMed ID: 30269244 [TBL] [Abstract][Full Text] [Related]
90. Adverse Drug Reactions in Hospitalized Pediatric Patients: A Prospective Observational Study. Kurian J; Mathew J; Sowjanya K; Chaitanya KR; Ramesh M; Sebastian J; Narayanappa D Indian J Pediatr; 2016 May; 83(5):414-9. PubMed ID: 26916890 [TBL] [Abstract][Full Text] [Related]
91. Paradoxical adverse drug reactions: descriptive analysis of French reports. Hakimi Y; Petitpain N; Pinzani V; Montastruc JL; Bagheri H Eur J Clin Pharmacol; 2020 Aug; 76(8):1169-1174. PubMed ID: 32418024 [TBL] [Abstract][Full Text] [Related]
92. [Analysis of adverse reactions and pharmacovigilance research to parenterally administered shuxuening]. Yang W; Xiang YY; Xie YM; Shen H Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):3013-8. PubMed ID: 24471322 [TBL] [Abstract][Full Text] [Related]
93. Reported Adverse Drug Reactions in Children and Adolescents Treated with Antipsychotics. Minjon L; van den Ban E; de Jong E; Souverein PC; Egberts TCG; Heerdink ER J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):124-132. PubMed ID: 30676073 [TBL] [Abstract][Full Text] [Related]
94. [Knowledge creation about adverse drug reactions in the paediatric population]. Aagaard L Ugeskr Laeger; 2013 Feb; 175(6):342-5. PubMed ID: 23402239 [TBL] [Abstract][Full Text] [Related]
95. Surveillance of adverse drug reactions at an adverse drug reaction monitoring centre in Central India: a 7-year surveillance study. Sharma M; Baghel R; Thakur S; Adwal S BMJ Open; 2021 Oct; 11(10):e052737. PubMed ID: 34607871 [TBL] [Abstract][Full Text] [Related]
96. Monitoring drug safety in Astrakhan, Russia. Kirilochev OO; Dorfman IP; Umerova AR Int J Risk Saf Med; 2015; 27 Suppl 1():S33-4. PubMed ID: 26639700 [TBL] [Abstract][Full Text] [Related]
97. Adverse event reporting tools and regulatory measures in India through outcome of Pharmacovigilance Programme of India. Prakash J; Sachdeva R; Shrivastava TP; Jayachandran CV; Sahu A Indian J Pharmacol; 2021; 53(2):143-152. PubMed ID: 34100398 [TBL] [Abstract][Full Text] [Related]
98. Psychiatric adverse drug reactions in the paediatric population. Ekhart C; Vries T; Hunsel FV Arch Dis Child; 2020 Aug; 105(8):749-755. PubMed ID: 32060030 [TBL] [Abstract][Full Text] [Related]
99. Preventability, predictability, severity and causality assessment of adverse drug reactions reported from a teaching hospital in chhattisgarh: A retrospective analysis. Keche Y; Gaikwad N; Dhaneria S J Family Med Prim Care; 2021 Jul; 10(7):2541-2545. PubMed ID: 34568133 [TBL] [Abstract][Full Text] [Related]